HIMS insider files Form 144 for 13,749 vested shares, $694K value
Rhea-AI Filing Summary
Hims & Hers Health, Inc. (HIMS) Form 144 records an insider notice for the proposed sale of 13,749 Class A shares through Fidelity Brokerage Services with an aggregate market value of $694,324.50, approximately tied to the reported outstanding share count of 217,641,958 shares. The proposed sale date is 09/17/2025. The shares were acquired on 09/15/2025 via restricted stock vesting and were paid as compensation. The filing lists prior Class A sales by the same person, Michael Y. Chi, totaling multiple transactions between June and September 2025 with gross proceeds shown per trade.
Positive
- Timely and detailed disclosure of the proposed sale, acquisition date, and nature of acquisition (restricted stock vesting).
- Broker and proposed sale date provided, improving transparency for market participants.
- Prior sales listed for the three-month period by the same insider, showing historical liquidity activity.
Negative
- None.
Insights
TL;DR: Routine insider sale notice reflecting recently vested shares and prior open-market sales; disclosure appears complete.
The Form 144 documents a proposed sale of 13,749 Class A shares acquired two days earlier by restricted stock vesting and designated as compensation. The transaction is to be executed via a national broker and the filing provides a clear link to prior insider disposals by the same individual across June–September 2025 with material gross proceeds per trade. For investors, this is a standard insider liquidity event rather than an operational disclosure; the filing fulfills Rule 144 notice requirements and lists outstanding shares and per-trade proceeds.
TL;DR: Compliance-focused filing showing timely reporting of vested shares and ongoing insider sales.
The document shows the insider represented no undisclosed material information and supplied dates and transaction nature (restricted stock vesting, compensation). The inclusion of prior sales in the three-month window improves transparency. There are no statements here about plan adoption dates or 10b5-1 instructions, so reliance on a trading plan is not asserted. From a governance perspective the filing meets Form 144 content expectations.